RU2206573C1 - Peptide family eliciting neurotropic property - Google Patents

Peptide family eliciting neurotropic property Download PDF

Info

Publication number
RU2206573C1
RU2206573C1 RU2001135362A RU2001135362A RU2206573C1 RU 2206573 C1 RU2206573 C1 RU 2206573C1 RU 2001135362 A RU2001135362 A RU 2001135362A RU 2001135362 A RU2001135362 A RU 2001135362A RU 2206573 C1 RU2206573 C1 RU 2206573C1
Authority
RU
Russia
Prior art keywords
pro
gly
phe
tyr
arg
Prior art date
Application number
RU2001135362A
Other languages
Russian (ru)
Inventor
И.П. Ашмарин
Л.Ю. Алфеева
Л.А. Андреева
И.А. Гривенников
В.А. Дубынин
А.А. Каменский
М.М. Козловская
Н.Г. Левицкая
Н.Ф. Мясоедов
В.Н. Незавибатько
С.Б. Середенин
Original Assignee
Институт молекулярной генетики РАН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Институт молекулярной генетики РАН filed Critical Институт молекулярной генетики РАН
Priority to RU2001135362A priority Critical patent/RU2206573C1/en
Application granted granted Critical
Publication of RU2206573C1 publication Critical patent/RU2206573C1/en

Links

Images

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

FIELD: organic chemistry, peptides, amino acids, medicine. SUBSTANCE: invention relates to peptides of the general formula: A-B-C-D-Pro-Gly-Pro-X where A means 0, -Met(0), -Met, -Thr, -Ala, - Lys, -Gly, -Glu, -Arg, -His, -Phe, -Tyr, -Trp; B means 0, -Glu, -Lys, - Tyr, -Gly, - Arg, -Val, -pro; C means 0, -His, -Pro, -Asp, -Gly, -Arg, - Tyr, -Val, -Phe; D means 0, -Phe, -His, -Arg, -Lys, - Ala, -Tyr, -Thr, - pro, -Ile; X means 0, -Ile eliciting neurotropic activity (0 means absence of amino acid) under condition that peptides: Glu-His-Phe-Pro-Gly-Pro, Thr-Lys-Pro-Arg-Pro-Gly-Pro, Tyr-Pro-Phe-Pro-Gly-Pro-Ile and Met- -Glu-His-Phe-Pro-Gly-Pro are excluded. These compounds are useful as neurotropic preparations for correction of neuro-psychical fatigues, enhancement of adaptive capacity of human body under extreme conditions and in different pathologies of central nervous system including psychical diseases. EFFECT: enhanced effectiveness and valuable medicinal properties of peptides. 3 cl, 12 tbl, 1 dwg

Description

Текст описания в факсимильном виде. Тт Description text in facsimile form. TT

Claims (3)

1. Пептиды общей формулы
А-Б-В-Г-Pro-Gly-Pro-X,
где А - О, -Met(O), -Met, -Thr, -Ala, -Lys, -Gly, -Glu, -Arg, -His, -Phe, -Tyr, -Trp;
Б-O, -Glu, -Lys, -Tyr, -Gly, -Arg, -Val, -Pro;
В-O, -His, -Pro, -Asp, -Gly, -Arg, -Tyr, -Val, -Phe;
Г-O, -Phe, -His, -Arg, -Lys, -Ala, -Tyr, -Thr, -Pro, -Ile;
X-O,-Ile,
обладающие нейротропной активностью (О обозначает отсутствие аминокислоты), при условии, что исключаются пептиды: Glu-His-Phe-Pro-Gly-Pro, Thr-Lys-Pro-Arg-Pro-Gly-Pro, Tyr-Pro-Phe-Pro-Gly-Pro-Ile и Met-Glu-His-Phe-Pro-Gly-Pro.1. Peptides of the General Formula
A-B-B-D-Pro-Gly-Pro-X,
where A is O, -Met (O), -Met, -Thr, -Ala, -Lys, -Gly, -Glu, -Arg, -His, -Phe, -Tyr, -Trp;
B-O, -Glu, -Lys, -Tyr, -Gly, -Arg, -Val, -Pro;
B-O, -His, -Pro, -Asp, -Gly, -Arg, -Tyr, -Val, -Phe;
G-O, -Phe, -His, -Arg, -Lys, -Ala, -Tyr, -Thr, -Pro, -Ile;
XO, -Ile,
possessing neurotropic activity (O denotes the absence of amino acids), provided that the peptides are excluded: Glu-His-Phe-Pro-Gly-Pro, Thr-Lys-Pro-Arg-Pro-Gly-Pro, Tyr-Pro-Phe-Pro -Gly-Pro-Ile and Met-Glu-His-Phe-Pro-Gly-Pro. 2. Пептид по п.1, полученный конденсацией фрагментов Б-В-Г и Pro-Gly-Pro и в случае необходимости присоединением к получившемуся пептиду с N-конца седьмой аминокислоты А. 2. The peptide according to claim 1, obtained by condensation of fragments B-B-D and Pro-Gly-Pro and, if necessary, adding to the resulting peptide from the N-end of the seventh amino acid A. 3. Пептид по пп.1 и 2, полученный синтезом гептапептида А-Б-В-Г-Pro-Gly-Pro и в случае необходимости присоединением с С-конца молекулы восьмой аминокислоты X. 3. The peptide according to claims 1 and 2, obtained by synthesizing the heptapeptide A-B-B-G-Pro-Gly-Pro and, if necessary, attaching the eighth amino acid molecule X from the C-terminus.
RU2001135362A 2001-12-27 2001-12-27 Peptide family eliciting neurotropic property RU2206573C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2001135362A RU2206573C1 (en) 2001-12-27 2001-12-27 Peptide family eliciting neurotropic property

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2001135362A RU2206573C1 (en) 2001-12-27 2001-12-27 Peptide family eliciting neurotropic property

Publications (1)

Publication Number Publication Date
RU2206573C1 true RU2206573C1 (en) 2003-06-20

Family

ID=29211244

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001135362A RU2206573C1 (en) 2001-12-27 2001-12-27 Peptide family eliciting neurotropic property

Country Status (1)

Country Link
RU (1) RU2206573C1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1621546A1 (en) * 2004-07-30 2006-02-01 Tecnogen S.C.P.A. Peptide ligands specific to immonoglobulins
RU2443711C1 (en) * 2011-02-02 2012-02-27 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Peptide possessing neurotropic properties
RU2443712C1 (en) * 2011-02-02 2012-02-27 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Peptide possessing neurotropic properties
RU2480234C1 (en) * 2012-03-01 2013-04-27 Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген" Method for prevention and treatment of carbohydrate and lipid metabolism disorder in metabolic syndrome and encephalopathy, use of tetrapeptide and pharmaceutical composition for prevention and treatment of such disorders
RU2544016C1 (en) * 2014-03-13 2015-03-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной генетики Российской академии наук (ИМГ РАН) UNIFORM DEUTERIUM- OR YTTRIUM-LABELLED His-Phe-Arg-Trp-Pro-Gly-Pro
RU2573823C2 (en) * 2014-03-26 2016-01-27 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Substituted dipeptides with neuropsychotropic activity
RU2687740C1 (en) * 2018-11-26 2019-05-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации USE OF PEPTIDE Gly-His-Lys-Pro-Gly-Pro TO ACHIEVE ANALGESIC EFFECT IN PAIN CAUSED BY TEMPERATURE IRRITATION
RU2705592C1 (en) * 2019-02-26 2019-11-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации USE OF PEPTIDE Gly-His-Lus-Gly-Pro TO ACHIEVE ANXIOLYTIC EFFECT
WO2020142103A1 (en) * 2019-01-04 2020-07-09 Avon Products, Inc. Oxidized derivatives of gdf-11 fragments

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1621546A1 (en) * 2004-07-30 2006-02-01 Tecnogen S.C.P.A. Peptide ligands specific to immonoglobulins
RU2443711C1 (en) * 2011-02-02 2012-02-27 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Peptide possessing neurotropic properties
RU2443712C1 (en) * 2011-02-02 2012-02-27 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Peptide possessing neurotropic properties
RU2480234C1 (en) * 2012-03-01 2013-04-27 Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген" Method for prevention and treatment of carbohydrate and lipid metabolism disorder in metabolic syndrome and encephalopathy, use of tetrapeptide and pharmaceutical composition for prevention and treatment of such disorders
RU2544016C1 (en) * 2014-03-13 2015-03-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной генетики Российской академии наук (ИМГ РАН) UNIFORM DEUTERIUM- OR YTTRIUM-LABELLED His-Phe-Arg-Trp-Pro-Gly-Pro
RU2573823C2 (en) * 2014-03-26 2016-01-27 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Substituted dipeptides with neuropsychotropic activity
RU2687740C1 (en) * 2018-11-26 2019-05-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации USE OF PEPTIDE Gly-His-Lys-Pro-Gly-Pro TO ACHIEVE ANALGESIC EFFECT IN PAIN CAUSED BY TEMPERATURE IRRITATION
WO2020142103A1 (en) * 2019-01-04 2020-07-09 Avon Products, Inc. Oxidized derivatives of gdf-11 fragments
CN113286576A (en) * 2019-01-04 2021-08-20 雅芳产品公司 Oxidized derivatives of GDF-11 fragments
CN113286576B (en) * 2019-01-04 2024-05-14 雅芳产品公司 Oxidized derivatives of GDF-11 fragments
RU2705592C1 (en) * 2019-02-26 2019-11-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации USE OF PEPTIDE Gly-His-Lus-Gly-Pro TO ACHIEVE ANXIOLYTIC EFFECT

Similar Documents

Publication Publication Date Title
CN102573884B (en) Novel peptides isolated from spider venom, and uses thereof
RU2468080C2 (en) Novel class of therapeutic protein molecules
CA2513218C (en) Peptides and uses thereof for preventing and treating alzheimer's disease(ad)
AU2009248041B2 (en) Long-acting Y2 and/or Y4 receptor agonists
US11952432B2 (en) Cell-permeable stapled peptide modules for cellular delivery
CN108992661B (en) Application of polypeptide in preparation of intravenous, intraperitoneal or nasal administration medicine
RU2676713C2 (en) Therapeutic peptides
RU2206573C1 (en) Peptide family eliciting neurotropic property
KR100860654B1 (en) Antagonists of the Bradykinin B1 Receptor
EA011037B1 (en) Oligomeric peptides and their use for the treatment of hiv infections
US5585353A (en) Antibiotic peptides containing D-amino acids
Machado et al. Synthesis and properties of cyclic gomesin and analogues
WO2023214576A1 (en) Cyclic compound having selective kras inhibitory effect on hras and nras
CN109265557A (en) Application of ziconotide and TAT peptide fusion polypeptide in preparation of medicine
CN109265558A (en) Application of improved ziconotide in preparation of medicines
RU2540012C2 (en) Motilin-like peptide compound having imparted transmucosal absorbing ability
CN109232744A (en) Improved ziconotide
JPH07501820A (en) Compositions and treatments with bioactive peptides and chelating agents
CN109232745A (en) Polypeptide capable of passing blood brain barrier
WO2021126827A1 (en) Structurally-stabilized oncolytic peptides and uses thereof
JP4160505B2 (en) Use of peptides containing post-translational type modifications in the concept of treatment of autoimmune diseases
WO2020196315A1 (en) Promotor for permeation into cell layer, composition for facilitating drug agent absorption, and pharmaceutical composition
US20170232057A1 (en) Opioid peptide
RU2144038C1 (en) Peptide used for inhibition of pepsin release, pharmaceutical composition
WO2023215784A1 (en) Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof